Cargando…
Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis
Immune-related adverse events represent a major hurdle to the success of immunotherapy. The immunological mechanisms underlying their development and relation to antitumor responses are poorly understood. By examining both systemic and tissue-specific immune changes induced by combination anti–CTLA-...
Autores principales: | Nahar, Kazi J., Marsh-Wakefield, Felix, Rawson, Robert V., Gide, Tuba N., Ferguson, Angela L., Allen, Ruth, Quek, Camelia, da Silva, Ines Pires, Tattersal, Stephen, Kiely, Christopher J., Sandanayake, Neomal, Carlino, Matteo S., McCaughan, Geoff, Wilmott, James S., Scolyer, Richard A., Long, Georgina V., Menzies, Alexander M., Palendira, Umaimainthan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675442/ https://www.ncbi.nlm.nih.gov/pubmed/36173679 http://dx.doi.org/10.1172/jci.insight.157839 |
Ejemplares similares
-
Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020) -
Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma
por: Marsh-Wakefield, Felix, et al.
Publicado: (2022) -
Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
por: Lee, Hansol, et al.
Publicado: (2021) -
Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
por: Zhang, Eva, et al.
Publicado: (2021) -
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)